Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of nivolumab + daratumumab ± low-dose cyclophosphamide in relapsed/refractory multiple myeloma
2017-000169-60Phase 2Terminated
- Sponsor
- VU University Medical Center
- Start
- Apr 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of nivolumab, daratumumab and cyclophosphamide in multiple myeloma (MM) (2 arms), sponsored by VU University Medical Center. Primary endpoint: Primary endpoint (Part A). Started Apr 2017; status: terminated.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-000169-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000169-60.